Pivotal Vaccine Trial Results
Vaxcyte Announces Upcoming Phase 3 Results for Pneumococcal Vaccine Candidate VAX-31
Anonymous
Key Points
1
The Oct. 5 webcast and conference call was scheduled for 8 a.m. ET (5 a.m. PT); Vaxcyte said the recording would remain available on its website for at least 30 days.
2
Vaxcyte said its VAX-24 candidate had already generated positive Phase 2 results in adults and infants and was designed to cover more serotypes than any pneumococcal conjugate vaccine then on the market.
3
The company said VAX-31 and VAX-24 aim to cover circulating serotypes associated with a significant share of invasive pneumococcal disease, high case-fatality rates, antibiotic resistance and meningitis, while retaining coverage of previously circulating strains.
4
Beyond its pneumococcal candidates, Vaxcyte is developing VAX-A1 for Group A Streptococcus and VAX-GI for Shigella; it also described VAX-XL as an earlier-stage candidate using its carrier-sparing, site-specific conjugation technology to seek broader coverage.
Vaxcyte's experimental pneumococcal vaccine VAX-31 met all primary endpoints in its pivotal Phase 3 trial, clearing a major hurdle toward FDA approval. The 31-valent vaccine candidate demonstrated strong immune responses against a broad range of disease-causing pneumococcal strains in adults, according to Market Screener. The company plans to file for FDA authorization in 2028.
VAX-31 is designed to protect against invasive pneumococcal disease and pneumococcal pneumonia by covering circulating strains linked to antibiotic resistance, high death rates, and meningitis. RTTNews reported the vaccine met noninferiority goals compared to existing shots like Prevnar 20 and Capvaxive. Vaxcyte also advanced an earlier 24-valent version, VAX-24, which showed positive Phase 2 results in both adults and infants.
Broad-Spectrum Coverage Across 31 Serotypes
VAX-31 targets 31 different pneumococcal serotypes — far more than current vaccines on the market. Grafa confirmed the vaccine met all primary immunogenicity endpoints, meaning it successfully triggered immune system responses against each target strain. This breadth is critical because no single pneumococcal strain causes all infections. The vaccine aims to cover strains responsible for the majority of serious pneumococcal disease worldwide.
Comparison With Existing Pneumococcal Vaccines
VAX-24, Vaxcyte's earlier candidate, was already designed to cover more serotypes than any pneumococcal conjugate vaccine then available. Market Screener noted that VAX-31 goes even further, adding seven additional serotypes. Both candidates retain coverage of previously circulating strains while targeting newer disease-causing types. This dual coverage matters because older strains still circulate in some populations.
RTTNews reported VAX-31 showed noninferiority against Prevnar 20 and Capvaxive, the leading pneumococcal vaccines currently on the market. This means VAX-31 triggered immune responses at least as strong as these established shots. Prevnar 20 covers 20 serotypes, so VAX-31's 31-serotype approach represents a significant expansion in potential disease coverage.
Targeting Antibiotic Resistance and High-Fatality Strains
Pneumococcal disease kills roughly 5% to 30% of patients who develop sepsis or meningitis, depending on the strain and patient age. VAX-31 prioritizes serotypes linked to antibiotic-resistant infections — a growing public health threat. Market Screener noted the vaccine targets strains associated with high case-fatality rates. Meningitis, caused by certain pneumococcal types, carries especially high mortality risk despite treatment.
Vaxcyte's Broader Pipeline Beyond Pneumococcus
Pneumococcal vaccines are just one focus for Vaxcyte. The company is also developing VAX-A1 for Group A Streptococcus infections and VAX-GI to prevent Shigella disease, a bacterial infection that causes severe diarrhea. Market Screener reported that VAX-XL represents an even earlier-stage candidate using the company's carrier-sparing conjugation technology. This manufacturing approach may eventually enable coverage of even more serotypes in future vaccines.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
18
Articles
82
Reach
100
A
AnonymousAuthor
